Today let’s check out Akorn (AKRX), a pharmaceutical company based in Illionois. The firm develops specialty drugs for use in ophthalmology, hospitals and as injectables. Last month the drugmaker reported second-quarter earnings that beat estimates and also raised its guidance. The stock is also featured on the IBD 50 list. Key Fundamentals For this quarter, Wall St. anticipates the company’s earnings will grow 66%.